Form 4: Twist Bioscience CEO Sells Shares for Tax Obligations
Insider Transaction Report
Twist Bioscience CEO Emily M. Leproust sold 2,265 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.
Summary
- Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp (TWST), reported a transaction on September 8, 2025.
- The transaction involved the disposition of 2,265 shares of Common Stock at a price of $25.76 per share.
- This sale was mandated by the Issuer's equity incentive plans to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units and does not represent a discretionary trade.
- Following this transaction, Emily M. Leproust beneficially owns 634,740 shares of Common Stock directly.
- The reporting person also holds various employee stock options with exercise prices ranging from $5.95 to $67.85 and different vesting and expiration dates.
Sentiment
Score: 5
Explanation: The transaction is a routine, non-discretionary 'sell to cover' for tax purposes, which is a neutral event. It does not reflect a change in management's sentiment towards the company's prospects.
Positives
- The underlying event for the share sale was the vesting of Restricted Stock Units, indicating compensation realization for the CEO.
- Significant holdings of employee stock options provide long-term incentive and align management's interests with shareholder value creation.
Negatives
- A reduction in direct beneficial ownership of common stock by 2,265 shares, although non-discretionary.
Future Outlook
This filing, a Form 4, primarily reports an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.
Management Comments
- "The sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person."
Industry Context
This Form 4 filing is specific to an insider transaction and does not provide information directly related to broader industry trends or competitive landscape within the biotechnology or synthetic biology sector.
Stakeholder Impact
- Shareholders: The transaction is a routine 'sell to cover' for tax purposes, which is generally not viewed negatively as it's non-discretionary. The CEO retains substantial equity, maintaining alignment of interests.
- Employees: The equity incentive plans, which led to the RSU vesting, are a key component of executive compensation and retention strategies.
Next Steps
- Ongoing vesting of various employee stock options according to their respective schedules, subject to continuous service.
Key Dates
| Date | Description |
|---|---|
| 09/01/2016 | Vesting start date for employee stock option with an exercise price of $5.95. |
| 09/28/2017 | Vesting start date for employee stock option with an exercise price of $8.82. |
| 10/31/2019 | Vesting start date for employee stock option with an exercise price of $26.66. |
| 10/24/2020 | Vesting start date for employee stock option with an exercise price of $23.33. |
| 09/01/2020 | Grant date for performance stock options with an exercise price of $67.85. |
| 12/19/2022 | Performance stock options with an exercise price of $67.85 vested and became exercisable due to performance criteria being met. |
| 09/08/2025 | Date of common stock transaction (sale). |
| 09/10/2025 | Signature date of the reporting person's attorney-in-fact. |
| 09/28/2025 | Expiration date for employee stock option with an exercise price of $5.95. |
| 09/28/2027 | Expiration date for employee stock option with an exercise price of $8.82. |
| 11/18/2028 | Expiration date for employee stock option with an exercise price of $26.66. |
| 10/23/2029 | Expiration date for employee stock option with an exercise price of $23.33. |
| 08/31/2030 | Expiration date for employee stock option with an exercise price of $67.85. |
Recommendation
holdThe filing details a routine, non-discretionary 'sell to cover' transaction by the CEO to satisfy tax obligations on vested equity. This event does not reflect a change in management's outlook or a discretionary decision to reduce exposure, and therefore, does not warrant a change in investment recommendation based solely on this filing. The CEO retains significant beneficial ownership and stock options, indicating continued alignment with shareholder interests.
Keywords
Twist Bioscience, TWST, Form 4, Insider Transaction, CEO, Emily Leproust, Stock Sale, Tax Withholding, Restricted Stock Units, Employee Stock Options
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.